Rohan Halder

Clinical hematologist; Transplant physician

[Rohan Halder @Rohanhematdoc]

Now that we have commercial access to BCMA Bispecifics in Myeloma, how important is it to have an assay for sBCMA? How would one use it in clinical practice?

[Rohan Halder @Rohanhematdoc]

@End_myeloma A significant proportion of patients cannot afford anti CD38 mabs, carfil becomes the usual go to 2nd line due to affordability. It used to be hard to accrue patients.

[Rohan Halder @Rohanhematdoc]

@End_myeloma For me the trial was way ahead of its time considering the fact that, anti- CD38 exposure in first line or even at 1st relapse was miniscule in daily practice. It was difficult to find patients who were dara exposed and carfil unexposed

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASCO26 #mmsm Oral sessions myeloma

PERSEUS outcomes based on new definition of high risk disease

Sustained MRD negativity seem to make the outcome of high risk similar to standard risk, imp to be sustained over multiple years

[Rohan Halder @Rohanhematdoc]

@TalhaBadarMD Yes, we do that

[Rohan Halder @Rohanhematdoc]

A thank you to all the Co authors in the study and of course the patients. @dbhurani @Reema_Shayra
#Thalassemia #QoL #HSCT

[Rohan Halder @Rohanhematdoc]

India faces a major healthcare burden of Transfusion Dependent Thalassemia.
Transplant is a curative treatment available for patients who have a Matched sibling donor.
An important question that arises is does transplant make a difference in long term quality of life

[Rohan Halder @Rohanhematdoc]

Transplant had a profound, long-term improvement in the multi-dimensional quality of life for children suffering from beta -thalassemia major.
Please find the link to the study. https://t.co/IqXMsnrcmv

[Rohan Halder @Rohanhematdoc]

Graft versus host disease had a negative impact on quality of life.

[Rohan Halder @Rohanhematdoc]

Used The PedsQL 4.0 Generic Core Scales to assess QOL. Significant Overall Improvement: The transplant (Tx) group scored significantly higher across all domains of health-related quality of life compared to the non-transplant (NTx) group (p < 0.05). This includes improvements

[Rohan Halder @Rohanhematdoc]

@HiraSMian @rajshekharucms @Rfonsi1 @RahulBanerjeeMD @DrRakeshPopat @bdermanmd @HadidiSamer I had the opportunity to use Elrana as a part of CUP in RRMM. The peripheral neuropathy/GBS was so debilitating that the patient said he had had enough of the drug, wanted it stopped for him.

[Daniel Auclair @AuclairDan]

3/ @ASCO #ASCO26 #myeloma #mmsm

- Impact of 5-Year Sustained MRD negativity in FORTE
https://t.co/9qtljfGXeV

- cfDNA WGS vs Mass Spec
https://t.co/TykNVfinS1

And one bonus thought-provoking on differences in access to CARTs
https://t.co/PxyXNAwEWm

[Rohan Halder @Rohanhematdoc]

@Papa_Heme I hope you are not being sarcastic.
An expert once told me what are you gonna do with it if you had access?

[Rohan Halder @Rohanhematdoc]

@BloodCancerJnl Would be keen to understand what they do in a CHIP clinic? And what profile of patients are seen in a CHIP clinic

[Rohan Halder @Rohanhematdoc]

How do you manage Progressive Disease in Myeloma post Bispecifics ( Teclistamab )? Is there any approach?
Can we induce sensitivity of Bispecifics- Plasma exchange+/-DTPACE/IMid like Therapy?
@RahulBanerjeeMD @VincentRK @myelomaMD @Rfonsi1 @rajshekharucms @kansagraM